Sage Bionetworks Announces Oncology Research Partnership with Pfizer
News Jan 18, 2010
Sage Bionetworks has announced a new research partnership with Pfizer, Inc. to build, analyze and exploit advanced network models of cancer.
Pfizer will provide research funding to Sage to analyze large, globally coherent datasets from Pfizer, Sage and the public domain. Through innovative network biology analysis Sage will use the genetic, molecular and clinical information to create predictive computational disease models. These models will help identify therapeutic targets for oncology drug development as well as aid in evaluating the efficacy and safety of drug development candidates.
“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets.”
“Our collaboration with Pfizer will help develop more innovative and more effective disease models and in turn help define specific patient sub-populations most likely to respond to new therapies,” said Dr. Stephen Friend, President of Sage Bionetworks.
“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets,” Dr. Friend added. “Data and models from the collaboration will become available in the Sage repository one year following the completion of the project expanding the datasets publicly available.”
Machine Learning to Increase the Pace of Brain Imaging AnalysisNews
New approach could allow doctors or researchers to quickly identify the data they need, and then rapidly fill in the fine details, making the process faster and more accurate.READ MORE
Mechanism of ApoE4 Gene Toxicity in Alzheimer's Disease Neurodegeneration SolvedNews
ApoE4 exacerbates the brain damage caused by toxic tangles of Alzheimer's-associated protein, tau.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE